🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

47 results for “Bayer AG” Clear

  1. BAY 3427080, BAY 3427080 60 mg capsules placebo

    Bayer AG

    Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  2. BAY 94-8862, Placebo to Finerenone 10 film-coated tablets, Placebo to BAY 948862, BAY 948862, Placebo to Finerenone 20 film-coated tablets, Finerenone

    Bayer AG

    Proteinuria, Chronic kidney disease

    phase 3 small molecule active

    1 trial

  3. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  4. Finerenone Bayer, Placebo BAY 948862, BAY 94-8862, Placebo BAY 948862 tablets, Finerenone, Finerenone

    Bayer AG

    Heart failure due to systemic left ventricular systolic dysfunction

    phase 3 small molecule active

    1 trial

  5. Finerenone, BAY 94-8862, BAY 948862, Finerenone Bayer

    Bayer AG

    Treatment of children with chronic kidney disease and proteinuria

    phase 3 small molecule active

    1 trial

  6. Finerenone, Finerenone Bayer, BAY 94-8862, Finerenone

    Bayer AG

    Heart failure due to systemic left ventricular systolic dysfunction

    phase 3 small molecule active

    1 trial

  7. Finerenone, Placebo, Placebo, BAY 94-8862

    Bayer AG

    Non-diabetic chronic kidney disease

    phase 3 small molecule active

    1 trial

  8. Jivi 500 IU powder and solvent for solution for injection, Jivi 1000 IU powder and solvent for solution for injection

    Bayer AG

    Severe hemophilia A (<1% FVIII:C)

    phase 3 small molecule active

    1 trial

  9. BAY 1021189

    Bayer AG

    Chronic heart failure with reduced ejection fraction

    phase 2 small molecule active

    1 trial

  10. BAY 2599023

    Bayer AG

    Hemophilia A

    phase 2 small molecule active

    1 trial

  11. BAY 2927088 Bayer (CM), BAY 2927088 Bayer (CM), BAY 2927088, BAY 2927088 Bayer

    Bayer AG

    HER2 mutation, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  12. BAY 3283142, BAY 3283142 PLACEBO, BAY 3283142, BAY 3283142

    Bayer AG

    Chronic kidney disease

    phase 2 small molecule active

    1 trial

  13. BAY 3713372 Bayer, BAY 3713372 Bayer, -, -, -, -

    Bayer AG

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  14. BAY 73-4506, BAY 734506

    Bayer AG

    Solid malignant tumors

    phase 2 small molecule active

    1 trial

  15. Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

    Bayer AG

    "Patients with interstitial lung disease associated pulmonary hypertension"

    phase 2 other active

    1 trial

  16. Kerendia 10 mg film coated tablets, Kerendia 20 mg film-coated tablets, Finerenone/Kerendia 10mg and 20mg Placebo equal to test product except active substance, Empagliflozin/Jardiance 10mg Placebo equal to test product except active substance, Jardiance 10 mg film-coated tablets

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  17. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  18. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  19. Placebo to BAY 3401016, BAY 3401016

    Bayer AG

    Alport Syndrome, Chronic kidney disease

    phase 2 small molecule active

    1 trial

  20. Riociguat Bayer, Riociguat Bayer, Placebo for riociguat, Riociguat Bayer

    Bayer AG

    Patients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)

    phase 2 small molecule active

    1 trial

  21. placebo of BAY 3427080, BAY 3427080

    Bayer AG

    Sleep disturbances associated with menopause

    phase 2 small molecule active

    1 trial

  22. (22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease.

    Bayer AG

    Chronic kidney disease, Coronary artery disease

    phase 1 other active

    1 trial

  23. A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, how it acts on different tumors in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  24. A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose when given alone or with pembrolizumab in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources